Results 41 to 50 of about 17,861,189 (258)

Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

BMC Health Services Research, 2023
Background The incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study performed a long-term economic evaluation of the first-line treatment strategies ibrutinib (IB) or bendamustine (
Yuan Hong, Xichuang Chen, Yuanquan Hong, Xingfang Xiao, Yan Wang, Xiaohong You, Jingyi Mi, Tao Zhou, Panpan Zheng, Zhihu Huang   +9 more
doaj   +1 more source

“We Cannot Talk as a Family”: Complexities of Survivorship Communication Among Hispanic/Latino Young Adult Survivors of Childhood Cancer, Parents, and Clinicians

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Young adult childhood cancer survivors (YA‐CCS) have an increased risk of treatment‐related health complications throughout their lives. Lifelong survivorship care is recommended, yet many YA‐CCS experience disruptions in care during pediatric‐to‐adult transitions and do not receive recommended survivorship care.
Kevin Shanchen Pu, Nicole Fernández‐Viña, Briana C. Martin‐Villa, Daniela Ramirez, Rebecca M. Lewinsohn, Mary Smith, Heidi Boynton, Lidia Schapira, Stephanie M. Smith   +8 more
wiley   +1 more source

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK

ERJ Open Research, 2021
UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with ...
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, Stuart J. Mealing, Oyinkansola Solanke, Nancy Risebrough, Afisi S. Ismaila   +6 more
doaj   +1 more source

Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis

, 2021
Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive ...
S Bryan (13303992), L Engel (12537844), DGT Whitehurst (14466603)   +2 more
core  

Estimating (quality-adjusted) life-year losses associated with deaths: with application to COVID-19 [PDF]

, 2021
Many epidemiological models of the COVID‐19 pandemic have focused on preventing deaths. Questions have been raised as to the frailty of those succumbing to the COVID‐19 infection.
Ankur Pandya, Goldstein, Daniel, David J. Vanness, Briggs, Andrew, Pandya, Ankur, Rachel Meacock, Andrew H. Briggs, Meacock, Rachel, Wisløff, Torbjørn, Daniel A. Goldstein, Kirwin, Erin; id_orcid, Erin Kirwin, Vanness, David, Torbjørn Wisløff, Meacock, Rachel; id_orcid   +14 more
core   +1 more source

Identifying Patterns of Hospitalizations Among Childhood Cancer Survivors: A Population‐Based Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Childhood cancer survivors (CCSs) experience more hospitalizations than the general population. We aimed to identify distinct hospitalization patterns among Queensland CCSs and the associated characteristics. Methods Cases (aged ≤14 years) diagnosed between 1995 and 2019 while residents of Queensland were identified through the ...
Hai Pham, Teyl Engstrom, Peter Baade, Natalie Bradford, Sarah Pont, Louise Marquart‐Wilson, Natasha Nassar, Jason D. Pole   +7 more
wiley   +1 more source

Pharmacoeconomic analysis of the use of tocilizumab in therapy for rheumatoid arthritis:imitation simulation

Научно-практическая ревматология, 2010
Heavy economic expenses for treatment with genetic engineering biologicals (GEB) in patients with rheumatoid arthritis (RA) determine what strategies are most optimal in terms of both their clinical efficiency and economic constituent should be sought ...
Dmitry Vladimirovich Goryachev, Sh F Erdes, E L Nasonov   +2 more
doaj   +1 more source

One-way sensitivity analysis on incremental cost per quality-adjusted life-year (ICER) gained by dabigatran 150mg.

, 2013
One-way sensitivity analysis on incremental cost per quality-adjusted life-year (ICER) gained by dabigatran 150mg.
Gergory Cheng (318744), Kia K. N. Tsui (318738), Raymond S. M. Wong (318741), Joyce H. S. You (318736)   +3 more
core   +1 more source

Bone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.
Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Rebecca J. Deyell, Lesleigh Abbott, Tony H. Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran   +21 more
wiley   +1 more source

Intervention of pharmaceutical care on the quality-adjusted life years in diabetic foot ulcer patients–A randomized controlled study

Journal of Education and Health Promotion
BACKGROUND: Diabetic foot ulcer (DFU) is one of the reasons for hospitalization among diabetic patients. The objective is to study the impact of pharmaceutical care on quality-adjusted life years (QALY) in DFU patients.
Barma Naga Raju, Uday Venkat Mateti, Rajashekar Mohan, Caren D’Souza, Neevan D’Souza   +4 more
doaj   +1 more source